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XObjectives:Heart transplantation in patients with adult congenital heart disease is increasing, yet no large studies
have defined how this subgroup differs from other adult recipients. We investigated outcomes and risk factors for
mortality and retransplantation among patients with adult congenital heart disease compared with adult recipients.
Methods: A review was performed of 18- to 45-year-old patients undergoing heart transplantation from 1990–
2008 reported to the United Network for Organ Sharing database. Trends were compared between 2 eras: era 1
(1990–1998) and era 2 (1999–2008). Multivariable semiparametric hazard models identified factors associated
with time-related death and retransplantation.
Results: Of 8496 patients identified, 575 had adult congenital heart disease. The prevalence of heart transplan-
tation among adult recipients decreased by 28% over time (P< .001) and increased among patients with adult
congenital heart disease by 41% (P<.001). Induction therapy use was less in patients with adult congenital heart
disease (66%) compared with that seen in adult recipients (71%, P ¼ .02). Steroid maintenance was less in pa-
tients with adult congenital heart disease (92%) compared with that seen in adult recipients (97%, P< .001).
Post–heart transplantation survival among adult recipients improved over time (P ¼ .02) but not among patients
with adult congenital heart disease (P¼ .81). Overall post–heart transplantation mortality (P¼ .006) and retrans-
plantation (P ¼ .03) were significantly higher for patients with adult congenital heart disease than for adult re-
cipients, mainly because of an early hazard phase. Adult congenital heart disease was a risk factor for both
death (P<.001) and retransplantation (P ¼ .04). Any induction therapy and steroid maintenance was associated
with improved survival for all recipients (P ¼ .001).
Conclusions: Adult congenital heart disease represent an increasing proportion of heart transplant recipients.
Compared with adult recipients, patients with adult congenital heart disease experience higher post–heart trans-
plantation mortality and retransplantation. Immunosuppression differs among patients with adult congenital heart
disease and adult recipients. Further studies should investigate whether post–heart transplantation outcomes
would be improved by more aggressive induction therapy or judicious steroid tapers. (J Thorac Cardiovasc
Surg 2010;140:161-8)Advances in surgical and medical management have greatly
improved the long-term survival of patients with congenital
heart disease.1-3 However, cardiac dysfunction can occur
after palliative or corrective surgery and is the most
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The Journal of Thoracic and Cacongenital heart disease.4 A recent study5 reported that
20% of patients with congenital heart disease can have heart
failure necessitating heart transplantation (HTx). This patient
population presents multiple unique surgical and medical
challenges that complicate cardiac transplantation given their
complex anatomy, prior surgical and interventional proce-
dures, and frequently increased pulmonary vascular resis-
tance from long-standing congestive heart failure or cyanosis.
Coupled with the added complexity of HTx in patients
with adult congenital heart disease (ACHD) compared
with other adult recipients (ARs), patients with ACHD are
likely to comprise an increasing number of HTx recipients
in the near future.1,3,4 Many of these are anticipated to be
single-ventricle patients, a subgroup whose outcomes might
be less favorable than those patients with biventricular phys-
iology.4,6 Despite these changes in the ACHD recipient pool,
preoperative selection and postoperative management of
patients with ACHD and ARs have been similar without
evidence supporting this approach. Aside from the annualrdiovascular Surgery c Volume 140, Number 1 161
Abbreviations and Acronyms
ACHD ¼ adult congenital heart disease
AR ¼ adult recipient
CHD ¼ congenital heart disease
HTx ¼ heart transplantation
RTx ¼ retransplantation
UNOS ¼ United Network for Organ Sharing
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registry reports,1 which include a brief summary of overall
outcomes, there are only single-institution reports for post-
transplantation outcomes in patients with ACHD. Consider-
ing the rapidly increasing population of patients with
ACHD, a comparison of posttransplantation management
strategies and outcomes to ARs based on cumulative United
Network for Organ Sharing (UNOS) experience is timely.
We therefore undertook this study to evaluate current
management strategies for ACHD after HTx, to identify de-
terminants associated with mortality and retransplantation
(RTx), and to compare these with AR outcomes.MATERIALS AND METHODS
Patients
Using the UNOS database from 1990–2008, we identified all recipients
between the ages of 18 and 45 years undergoing isolatedHTx.We chose this
age group to capture the vast majority of patients with ACHD and to com-
pose a more homogeneous pool of recipients with more closely approxi-
mated demographics and whose outcomes were less likely to be
influenced by other medical comorbidities typical of older ARs but rare in
patients with ACHD. Patients were grouped into broad diagnostic categories
(congenital heart disease, dilated cardiomyopathy, ischemic cardiomyopa-
thy, restrictive cardiomyopathy, and other), as were immunosuppression
regimens to simplify analyses (Appendices 1 and 2). Patients without
follow-up information (n ¼ 583) were excluded.
Statistical Analysis
Overall descriptive statistics were computed. Recipient groups (ARs and
patients with ACHD) were compared by using the c2 test for categorical
variables or the t test for continuous variables. Percentages were calculated
by using the number of available data, with missing values indicated.
Trends were compared between 2 eras, era 1 (1990–1998) and era 2
(1999–2008), to capture changes in immunosuppression (ie, introduction
of mycophenolate mofetil and transition from cyclosporine to tacrolimus).
Time-related death and RTx were computed by using the Kaplan–Meier
method, and the log-rank statistic was used to determine differences be-
tween groups. Multivariable semiparametric hazard models identified fac-
tors associated with time-related death and RTx. SAS software, version
9.1 (SAS Institute, Inc, Cary, NC), was used for all analyses. Institutional
review board approval was obtained, but given the deidentified nature of
the UNOS database, patient consent was waived for this study.RESULTS
Case Mix
Demographics and clinical characteristics of the study pa-
tients are shown in Table 1. Of 8496 cases identified, 6.8%162 The Journal of Thoracic and Cardiovascular Surg(n¼ 575) were patients with ACHD, and 93.2% (n¼ 7921)
were ARs. The AR group was comprised of the following
diagnostic subgroups: dilated cardiomyopathy, 46.4%
(n ¼ 3939); inoperable coronary artery disease (nondilated
ischemic cardiomyopathy), 19.1% (n¼ 1624); hypertrophic
cardiomyopathy, 2.5% (n ¼ 215); valvular heart disease,
2.7% (n ¼ 231); and restrictive cardiomyopathy, 1.9%
(n ¼ 163). Patients with ACHD were younger, had longer
ischemic and waitlist times, and were more likely to have
preoperative extracorporeal membrane oxygenation support
(P< .05 for all). In contrast, status 1 prevalence was higher
among ARs than patients with ACHD (P< .001). Between
eras 1 and 2, the frequency of HTx decreased by 28% in
ARs (4033 to 2888, P<.001) but increased by 41% among
patients with ACHD (239 to 336, P< .001).
Immunosuppression Regimen
Induction therapy. Immunosuppression regimens among
groups are shown in Table 1. Overall use of induction ther-
apy with standard agents, including antithymocyte globulin,
Muromonab-CD3, and interleukin 2 receptor antagonists,
was less prevalent in patients with ACHD (66.5%) com-
pared with that seen in ARs (71.2%, P ¼ .02). In particular,
patients with ACHDwere less likely than ARs to receive ste-
roid induction (72.8% vs 77.6%, P ¼ .01) without a corre-
sponding increase in alternative agents (Figure 1). In
general, induction therapy was less prevalent among both
groups over time; however, this might represent an underre-
porting of newer agent use, including interleukin 2 antago-
nists, within the UNOS database.
Maintenance therapy. Maintenance therapy was similar
among patients with ACHD and ARs, except that steroids
were less frequently used in patients with ACHD (92.1%)
than in ARs (96.6%, P < .001). Maintenance regimens
also changed over time in both groups. Decreased use of ste-
roids in patients with ACHD relative to ARs persisted in
both eras (Figure 1). Tacrolimus replaced cyclosporine as
the predominant calcineurin inhibitor, and azathioprine
was used more frequently for maintenance in patients with
ACHD than in ARs (86.8% vs 72.2%, P ¼ .02).
Mortality and RTx
There were 3208 total deaths during the study period,
yielding an overall mortality of 37.8%. Cause of death
was graft failure in 665 patients, cardiovascular failure in
733 patients, infection in 271 patients, malignancy in 156 pa-
tients, pulmonary failure in 81 patients, hemorrhage in 65 pa-
tients, technical in 8 patients, other in 492 patients, and
unknown in 737 patients. Cause of death was similar among
both groups, except patients with ACHD had a greater prev-
alence of death from early hemorrhage (n¼ 15 [2.6%]) com-
pared with ARs (n ¼ 76 [1%], P< .001), and ARs had
a greater prevalence of death from malignancy (n ¼ 152
[2.1%]) compared with patients with ACHD (n ¼ 4ery c July 2010
TABLE 1. Demographic characteristics among study patients
Variable Patients with ACHD (n ¼ 575) ARs (n ¼ 7921) P value
Age (y), mean  SD 28.3  8.1 35.4  7.9 <.001
Female sex, no. (%) 212 (37) 2476 (31) .005
Status 1, no. (%) 355 (62) 5809 (73) <.001
Waitlist time (d), median (range) 114 (0–2245) 74 (0–4318) <.001
Ischemic time (h), median (range) 3.8 (1–8.9) 2.9 (0.5–12) <.001
ECMO before transplantation, no. (%) 6 (1) 34 (0.4) .04
Immunosuppression regimens, no. (%)
Steroid induction 385 (72.8) 5268 (77.6) .01
OKT3 induction 56 (74.7) 600 (71.2) .52
Induction with any agent 358 (66.5) 5191 (71.2) .02
Cyclosporine maintenance 119 (99.2) 2074 (98.9) .36
Azathioprine maintenance 216 (90.8) 3294 (91.6) .65
Steroid maintenance 487 (92.1) 7010 (96.6) <.001
ACHD, Adult congenital heart disease; ARs, adult recipients; SD, standard deviation; ECMO, extracorporeal membrane oxygenation; OKT3, Muromonab-CD3.
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X[0.7%], P¼ .02). Freedom from death at 1, 10, and 15 years
for the entire study population was 86%, 54%, and 38%, re-
spectively (Figure 2), with similar crude mortality between
groups (227/575 [39%] vs 2981/7921 [38%], P ¼ .9). Im-
portantly, post-HTx survival among ARs improved over
time (era 1: 1- and 5-year survival of 85% and 67%, respec-
tively; era 2: 1- and 5-year survival of 87% and 71%, re-
spectively; P ¼ .02), whereas no era effect was seen
among patients with ACHD (era 1: 1- and 5-year survival
of 76% and 63%, respectively; era 2: 1- and 5-year survival
of 75% and 63%, respectively; P¼ .81; Figure 3). Kaplan–
Meier freedom from death was significantly higher for ARs
(1- and 10-year survival of 87% and 55%, respectively) than
for patients with ACHD (1- and 10-year survival of 76% and
52%, respectively, P ¼ .003), mainly because of an early
hazard phase (Figure 4).
Multivariable factors associated with increased mortality
included ACHD (P< .001), younger age (P ¼ .002), status
1 (P ¼ .03), longer ischemic times (P< .001), and female
sex (P¼ .04). Any induction therapy (P¼ .008) and steroid
maintenance therapy (P< .001) were associated with im-














FIGURE 1. Immunosuppression trends over time among patients with adult co
with ACHD significantly received less aggressive induction than ARs. In era 2, al
maintenance was still significantly lower in patients with ACHD compared with
SI, steroid induction; SM, steroid maintenance. )P< .05.
The Journal of Thoracic and Catant interaction term whereby patients with ACHD gained
an additional survival benefit with use of maintenance
steroids (P< .001, Table 2).
For the overall cohort, RTx was necessary in 273 (3.5%)
patients. There was a higher RTx rate in patients with ACHD
(n ¼ 27/575 [4.7%]) than in ARs (n ¼ 266/7921 [3.4%],
P ¼ .09). Kaplan–Meier freedom from RTx was greater
for ARs (1- and 10-year freedom of 99% and 91%, respec-
tively) than for patients with ACHD (1- and 10-year freedom
of 96% and 86%, respectively; P ¼ .04; Figure 5). Multi-
variable factors associated with an increased risk of RTx
included ACHD (P ¼ .03).
DISCUSSION
Wehave shown, using a large administrative database, that
mortality and RTx rates are higher after HTx for ACHD than
those for patients with other underlying diagnoses. Although
ARs have seen an improvement in these outcomes over
time, no era effect could be demonstrated for patients with
ACHD,mainly because of the persistent early attrition among
patients with ACHD in the first year after transplantation. Im-






ngenital heart disease (ACHD) and adult recipients (ARs). In era 1 patients
though the induction gap decreased among groups, the prevalence of steroid
that seen in ARs. AI, Any induction with standard agents excluding steroids;
rdiovascular Surgery c Volume 140, Number 1 163
FIGURE 2. Overall risk-unadjusted freedom from death after transplantation. Numbers at bottom inset show the number of patients remaining at risk.
Dashed lines enclose 95% confidence intervals.
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Xoverall proportion of the recipient pool (approximately 2%),
the incidence of HTx is increasing among patients with
ACHD in the recent era compared with ARs, in whom HTx
incidence has decreased. Certainly, inherent differences
among these groups, such as age, which we found to be
a risk factor for mortality, explain some of the variation in
post-HTx death and RTx. However, our study is unique in
that we have elucidated differences in immunosuppression
regimens among patients with ACHD and ARs that could
represent modifiable therapeutic targets. Specifically, more
aggressive induction therapy and use of steroid maintenance
therapy in patients with ACHD could lead to improved out-
comes.
Our data agree with the 24th Official Adult Heart Trans-
plant Report by Taylor and colleagues,1 which showed
that an underlying diagnosis of ACHD was a powerful
risk factor for 1-year mortality, with a 2- to 3-fold increase
in relative risk. Pigula and associates6 also found in a suba-
nalysis of 8 patients (of 33 undergoing combined cardiopul-
monary transplantation) that patients with ACHD had
significantly worse survival after HTx than ARs. The influ-
ence of underlying diagnosis of ACHD has been negligible
in other studies.2,3 Lamour and coworkees2 studied 24 pa-
tients older than 18 years with an underlying diagnosis of
congenital heart disease (CHD) who underwent HTx at their
institution from 1995–1998. These authors found similar
1-year survival (75%) among patients with ACHD to that
reported in our present study. However, post-HTx 1-year
survival among a control group in their study, which was
composed of 33 ARs, was only 79%, and they concluded
that outcomes for ARs and patients with ACHD are equiva-
lent.2 The Mayo Clinic reported excellent outcomes, with 16
patients having CHD, 11 of whomwere older than 18 years.3164 The Journal of Thoracic and Cardiovascular SurgActuarial survival was 86% at 5 years, although, similar to
our findings, these authors also noted an early hazard phase
for the patients with ACHD after HTx. Importantly, in the
Mayo Clinic series patients with CHD received aggressive
induction with steroids, OKT3, and azathioprine, and they
were maintained on prednisone (0.2 mg/kg) daily. Our
data would support that outcomes in patients with ACHD
could be improved by administering aggressive induction
and continued judicious use of steroids after HTx.
The lack of improved outcomes over time among patients
with ACHD, as opposed to ARs, is an important finding in
our analysis. The negligible era effect is mainly because of
the unmitigated early attrition among patients with ACHD,
which can be attributed to challenges within preoperative,
postoperative, and intraoperative care.3,4,7 We recognize
that our findings might seem contradictory in that induction
use and steroid maintenance decreased over time in both
groups, yet outcomes improved within ARs. However, it is
possible that we have failed to capture increased use of
newer induction agents, including interleukin 2 receptor
antagonists, which are underreported in our dataset. It is
also likely that the early hazard among patients with
ACHD is due to more complex perioperative factors that
have yet to be elucidated. Selection of patients with
ACHD with increased pulmonary vascular resistance for
isolated cardiac rather than combined cardiopulmonary
transplantation can be challenging.Many single-ventricle re-
cipients with failing Fontan circulation have systemic com-
plications, such as protein-losing enteropathy or systemic
arteriovenous or venovenous collaterals, which can compli-
cate intraoperative management and postoperative care.
Most recipients with ACHD have also had prior cardiac
surgery, and many have complex anatomy, both of whichery c July 2010
FIGURE 3. A, Risk-unadjusted freedom from death for adult recipients stratified by eras demonstrates an improvement in mortality over time, especially
within midterm survival. Note the areas of the curves between years 4 and 7 in which the confidence limits do not overlap. Era 1 (1990–1998) is depicted in
red, and era 2 (1999–2008) is depicted in blue. Solid circles represent censored patients. Numbers at inset show the number of patients remaining at risk.
Dashed lines enclose 95% confidence intervals. B, Risk-unadjusted freedom from death for patients with adult congenital heart disease was equivalent in
both eras. Era 1 (1990–1998) is depicted in red, and era 2 (1999–2008) is depicted in blue. Solid circles represent censored patients. Numbers at inset
show the number of patients remaining at risk. Dashed lines enclose 95% confidence intervals.
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Xnecessitate longer cardiopulmonary bypass and ischemic
times and contribute to postoperative coagulopathy and in-
creased infection risk.4,7
Certain factors that likely contribute to the difference in
posttransplantation outcomes among patients with ACHD
and ARs, including the precise congenital diagnosis, the
prevalence and distribution of recipient comorbidities, andThe Journal of Thoracic and Cathe number of prior cardiac procedures, could not be cap-
tured with the current dataset. Further elaboration of the in-
fluence of these variables using either the International
Society for Heart and Lung Transplantation database or
a more complete single-institution database is warranted.
However, our data suggest that a potentially modifiable
reason underlying the increased risk of death amongrdiovascular Surgery c Volume 140, Number 1 165
FIGURE 4. Risk-unadjusted freedom from death stratified by underlying diagnosis, either patients with adult congenital heart disease (ACHD) or adult re-
cipients (ARs). The blue line depicts ARs, and the red line depicts patients with ACHD. Survival is significantly better for ARs than for patients with ACHD,
mainly because of an early hazard phase representing increased postoperative mortality for patients with ACHD that persists to 2.5 years after transplantation.
Numbers at inset show the patients remaining at risk. Dashed lines enclose 95% confidence intervals.
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Xpatients with ACHD is a difference in postoperative immu-
nosuppression. Patients with ACHD were less likely to re-
ceive induction therapy and were less likely to be treated
with maintenance steroids. The risk of allograft rejection
is highest in the first several months after transplantation,
and cytolytic induction therapy, which rapidly depletes
recipient lymphocytes, might mitigate the risk of acute
rejection. Patients with ACHD might be at increased risk
for rejection because of increased levels of lymphocytotoxic
IgG class antibodies from multiple prior blood transfusions
or use of homograft implants.4,8,9 Unfortunately, data
regarding early rejection episodes were available in too few
patients within the UNOS dataset to allow a meaningful
analysis, although this will be an important focus for future







ACHD 0.67  0.15 1.96 <.001
Younger age 0.01  0.002 1.01 .003
Female sex 0.08  0.04 1.10 .03
Longer ischemic time 0.07  0.02 1.07 <.001
No steroid maintenance 0.78  0.09 2.18 <.001
No induction agent 0.19  0.07 1.22 <.001
Status 1 0.09  0.04 1.09 .03
Interaction term between ACHD
and steroid maintenance
 0.51 <.001
SE, Standard error; ACHD, adult congenital heart disease.
166 The Journal of Thoracic and Cardiovascular SurgWe also found that younger age and longer ischemic time
were risk factors for death. The 2007 International Society of
Heart and Lung Transplantation report similarly detailed that
extremes of age (<20 and>60 years), as well as longer du-
ration of ischemic time, were associated with an increased
risk of death.1 We anticipated that advanced age would be
an influential variable and therefore chose a study popula-
tion between 18 and 45 years to reduce this bias. It is unclear
what underlies the difference in postoperative immunosup-
pression therapy among patients with ACHD and ARs.
One possibility is that health care providers are reticent to
administer steroid maintenance in patients with ACHD be-
cause of concerns for late osteoporosis, avascular femoral
head necrosis, and accelerated coronary vasculopathy. A
less aggressive approach to induction therapy might simi-
larly belie an unfamiliarity regarding the possible effect of
newer medications on younger patients. We were not able
to gather data regarding the specialty (eg, pediatric cardiol-
ogists vs adult cardiologists) of post-HTx providers, but
prior reports, albeit not specific to HTx recipients, have dem-
onstrated that patients with ACHD fare better when cared for
within a children’s hospital environment by pediatric spe-
cialists who are more familiar with the complex anatomy
and physiology of these challenging patients.10,11
Limitations
Our study has several limitations, including all of those
that apply to any retrospective analysis of prospectively col-
lected data. Missing data regarding important outcomes, in-
cluding early rejection and immunosuppression regimens,ery c July 2010
FIGURE 5. Risk-unadjusted freedom from retransplantation stratified by underlying diagnosis, either patients with adult congenital heart disease (ACHD) or
adult recipients (AR). The blue line depicts ARs, and the red line depicts patients with ACHD. Although the difference is small, note the nearly overlapping
confidence intervals, the retransplantation rate is significantly higher for patients with ACHD than for ARs. Dashed lines enclose 95% confidence intervals.
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have biased our results. Data regarding panel-reactive anti-
body levels could be crucial to identifying additional inher-
ent differences among patients with ACHD and ARs but
were incompletely captured within the UNOS dataset.
More detailed information regarding the precise congenital
diagnosis, irrespective of whether death was related to graft
rejection, the incidence of chronic rejection, and the preva-
lence and distribution of comorbidities, would also have
contributed substantially to the study but is currently un-
available within our dataset. Finally, an analysis of outcomes
based on center volume and provider specialty, data unavail-
able in the present dataset, would have provided more in-
sight underlying the differences in management among
patients with ACHD and ARs.
CONCLUSIONS
Patients with ACHD represent an increasing proportion of
HTx recipients. Higher post-HTx mortality and RTx rates
amongpatientswithACHDcomparedwithARs are persistent
over time.Management of immunosuppression differs among
patients with ACHD and ARs. Further studies should investi-
gatewhether post-HTxoutcomeswould be improved bymore
aggressive induction therapy or judicious steroid tapers.The Journal of Thoracic and CaReferences
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APPENDIX 1. UNOS database codes used to define diagnostic groups
ACHD: 1203, 11205, 1206, 1207, 1500, 1501, 1502, 1548, 1549, 1600
Dilated cardiomyopathy: 1000,* 1001, 1002, 1003, 1004, 1005, 1006,
1007y
Nondilated ischemic cardiomyopathy: 1200
Hypertrophic cardiomyopathy: 1201
Valvular heart disease: 1202
Restrictive cardiomyopathy: 1050, 1051, 1052, 1053, 1054, 1099
Failed prior heart transplantation: 1100, 1101, 1102, 1103, 1104, 1105,
1106, 1199
ACHD, Adult congenital heart disease. *Code for idiopathic dilated cardiomyopathy.
yCode for ischemic dilated cardiomyopathy.
APPENDIX 2. Lexicon for grouping immunosuppression agents
Cyclosporine
Includes generic cyclosporine, Gengraf, Neoral, Sandimmune, and
cyclosporine
MMF
Includes mycophenolate mofetil and Myfortic
Any induction
Includes ATG, OKT3, and IL-2 receptor antagonists
MMF, Mycophenolate mofetil; ATG, antithymocyte globulin; OKT3, Muromonab-
CD3; IL-2, interleukin 2.
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